Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly's Lartruvo Scores Broad FDA Approval In Orphan Sarcomas

Executive Summary

Accelerated filing was supported by trial of patients with 25 subtypes of soft tissue sarcoma and confirmatory study will span 50 kinds.

Advertisement

Related Content

Curbing Cancer Drug Costs: Lartruvo Vial Sizes Designed To Reduce Waste
‘Regulatory Risk’: A New Factor In Risk/Benefit Equation At US FDA?
Lilly's Sarcoma Drug Likely To Be Used Widely Despite EU Conditional OK
Keeping Track: Oncology Approvals And Responses To Complete Response Letters
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Lilly’s Sarcoma Drug Lartruvo Latest To Test EU Conditional Approval System
Keeping Track: Lilly's Olaratumab, Cempra's Solithromycin, AAA's Lutathera Complete Submissions; End Of The Road For Rociletinib

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel